3‐Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP‐elicited damage both in vivo and in vitro
Authors:
Open Access
- 1 December 2006
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 20 (14) , 2496-2511
Abstract
We investigated the neuroprotective property of analogs of dextromethorphan (DM) in lipopolysaccharide (LPS) and 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) models to identify neuroprotective drugs for Parkinson's disease (PD). In vivo studies showed that daily injections with DM analogs protected dopamine (DA) neurons in substantia nigra pars compacta and restored DA levels in striatum using two different models for PD. Of the five analogs studied, 3‐hydroxymorphinan (3‐HM), a metabolite of DM, was the most potent, and restored DA neuronal loss and DA depletion up to 90% of the controls. Behavioral studies showed an excellent correlation between potency for preventing toxin‐induced decrease in motor activities and neuroprotective effects among the DM analogs studied, of which 3‐HM was the most potent in attenuating behavioral damage. In vitro studies revealed two glia‐dependent mechanisms for the neuroprotection by 3‐HM. First, astroglia mediated the 3‐HM‐induced neurotrophic effect by increasing the gene expression of neurotrophic factors, which was associated with the increased acetylation of histone H3. Second, microglia participated in 3‐HM‐mediated neuroprotection by reducing MPTP‐elicited reactive microgliosis as evidenced by the decreased production of reactive oxygen species. In summary, we show the potent neuroprotection by 3‐HM in LPS and MPTP PD models investigated. With its high efficacy and low toxicity, 3‐HM may be a novel therapy for PD.—Zhang, W., Shin, E‐J., Wang, T., Lee, P. H., Pang, H., Wie, M. B., Kim, W‐K., Kim, S‐J., Huang, W‐H., Wang, Y., Zhang, W., Hong, J‐S., Kim, H‐C. 3‐Hydroxymorphinan, a metabolite of dextromethorphan, protects nigrostriatal pathway against MPTP‐elicited damage both in vivo and in vitro . FASEB J. 20, 2496–2511 (2006)Keywords
This publication has 63 references indexed in Scilit:
- MPP + ‐induced COX‐2 activation and subsequent dopaminergic neurodegenerationThe FASEB Journal, 2005
- The dextromethorphan analog dimemorfan attenuates kainate‐induced seizures via σ1 receptor activation: comparison with the effects of dextromethorphanBritish Journal of Pharmacology, 2005
- 3‐Hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS‐induced neurotoxicityThe FASEB Journal, 2004
- TGF-β promotes survival on mesencephalic dopaminergic neurons in cooperation with Shh and FGF-8Neurobiology of Disease, 2004
- The antioxidant drink “effective microorganism-X (EM-X)” pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson’s diseaseJournal of Pharmacy and Pharmacology, 2004
- Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's diseaseThe FASEB Journal, 2003
- Critical role of microglial NADPH oxidase‐derived free radicals in the in vitro MPTP model of Parkinson's diseaseThe FASEB Journal, 2003
- Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's diseaseThe FASEB Journal, 2002
- Parkinson's disease: Neurodegenerative mechanisms and neuroprotective interventions?report of a workshopMovement Disorders, 1998
- Astroglial neurotrophic and neurite-promoting factorsPharmacology & Therapeutics, 1995